Mankind Pharma shares jump 9% post Q1 earnings. Should you buy?
The domestic business reported a robust 14% YoY growth in the quarter. The secondary sales saw an impressive growth of 12.5%, thereby outperforming the industry by 1.5 times. The company registered a volume growth of 4.3%, compared to the industry growth of 1.4%.
